SEC 13F Intelligence

Atlas Venture Associates Ix, LLC / NTLA

Atlas Venture Associates Ix, LLC’s Intellia Therapeutics Inc Position

Does Atlas Venture Associates Ix, LLC own Intellia Therapeutics Inc (NTLA)? Yes10.0K shares worth $316,200 (+2.69% of its 13F portfolio) as of Q3 2023.

Position Value
$316,200
Q3 2023
Shares
10.0K
% of Portfolio
+2.69%
Quarters Held
20
currently held

Position History NTLA

Reported value by quarter
Q4 ’18: $22MQ4 ’18Q1 ’19: $28MQ2 ’19: $26MQ3 ’19: $22MQ3 ’19Q4 ’19: $24MQ1 ’20: $20MQ2 ’20: $34MQ2 ’20Q3 ’20: $32MQ4 ’20: $88MQ1 ’21: $89MQ1 ’21Q2 ’21: $2MQ3 ’21: $1MQ4 ’21: $1MQ4 ’21Q1 ’22: $727,000Q2 ’22: $518,000Q3 ’22: $560,000Q3 ’22Q4 ’22: $348,900Q1 ’23: $372,700Q2 ’23: $407,800Q2 ’23Q3 ’23: $316,200filingsflow.com
QuarterSharesValue% of Portfolio
Q3 202310.0K$316,200+2.69%
Q2 202310.0K$407,800+2.23%
Q1 202310.0K$372,700+1.75%
Q4 202210.0K$348,900+1.74%
Q3 202210.0K$560,000+1.66%
Q2 202210.0K$518,000+1.18%
Q1 202210.0K$727,000+0.67%
Q4 202110.0K$1M+0.52%
Q3 202110.0K$1M+0.45%
Q2 202110.0K$2M+0.28%
Q1 20211.11M$89M+15.01%
Q4 20201.62M$88M+13.93%
Q3 20201.62M$32M+33.22%
Q2 20201.62M$34M+36.31%
Q1 20201.62M$20M+41.77%
Q4 20191.62M$24M+41.29%
Q3 20191.62M$22M+35.49%
Q2 20191.62M$26M+28.28%
Q1 20191.62M$28M+25.92%
Q4 20181.62M$22M+25.39%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Atlas Venture Associates Ix, LLC’s full portfolio or all institutional holders of NTLA.